Overview
Description
BridgeBio Pharma Inc. is a cutting-edge biotechnology company focused on discovering, developing, and delivering transformative medicines for patients with genetic diseases. The company's primary purpose is to bridge the gap in medical research and bring breakthrough therapies to those with rare and often overlooked genetic disorders. By utilizing a targeted approach, BridgeBio Pharma Inc. works across multiple sectors including dermatology, oncology, cardiology, neurology, and endocrinology. The company partners with academic institutions, research organizations, and industry leaders to harness the latest scientific advancements in genomics and biotechnology. Established with a mission to translate genetic research into real-world medical solutions, BridgeBio Pharma Inc. plays a significant role in the biopharmaceutical market. It is heavily involved in the early and late stages of drug development, positioning itself as a key player in the quest to address unmet medical needs. This focus on genetic-centric therapies underlines its importance in the rapidly evolving landscape of biotechnology and personalized medicine.
About
CEO
Dr. Neil Kumar Ph.D.
Employees
725
Address
3160 Porter Drive
Suite 250
Palo Alto, 94304, CA
United States
Suite 250
Palo Alto, 94304, CA
United States
Phone
650 391 9740
Website
Instrument type
Common stock
Sector
Healthcare
Industry
Biotechnology
Country
United States
MIC code
XNGS